JP2018537529A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537529A5 JP2018537529A5 JP2018544771A JP2018544771A JP2018537529A5 JP 2018537529 A5 JP2018537529 A5 JP 2018537529A5 JP 2018544771 A JP2018544771 A JP 2018544771A JP 2018544771 A JP2018544771 A JP 2018544771A JP 2018537529 A5 JP2018537529 A5 JP 2018537529A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- position corresponding
- peptide
- par2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000001014 amino acid Nutrition 0.000 claims 73
- 108090000765 processed proteins & peptides Proteins 0.000 claims 42
- 150000001413 amino acids Chemical class 0.000 claims 38
- 125000003275 alpha amino acid group Chemical group 0.000 claims 32
- 101001098560 Homo sapiens Proteinase-activated receptor 2 Proteins 0.000 claims 24
- 102000050100 human F2RL1 Human genes 0.000 claims 24
- 102000032628 PAR-2 Receptor Human genes 0.000 claims 19
- 108010070503 PAR-2 Receptor Proteins 0.000 claims 19
- 230000035772 mutation Effects 0.000 claims 17
- 229910052698 phosphorus Inorganic materials 0.000 claims 14
- 125000000539 amino acid group Chemical group 0.000 claims 12
- 230000002209 hydrophobic effect Effects 0.000 claims 12
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 10
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 9
- 150000008574 D-amino acids Chemical class 0.000 claims 9
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims 8
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 8
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims 8
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 239000004472 Lysine Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 229960002591 hydroxyproline Drugs 0.000 claims 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 5
- 108091035707 Consensus sequence Proteins 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 4
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 4
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims 4
- 229960002173 citrulline Drugs 0.000 claims 4
- 235000013477 citrulline Nutrition 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 3
- 102000004877 Insulin Human genes 0.000 claims 3
- 108090001061 Insulin Proteins 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- 229940125396 insulin Drugs 0.000 claims 3
- 125000003473 lipid group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- -1 tridecanoyl Chemical group 0.000 claims 3
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 claims 2
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 claims 2
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 claims 2
- 208000003251 Pruritus Diseases 0.000 claims 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000037431 insertion Effects 0.000 claims 2
- 238000003780 insertion Methods 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 150000003431 steroids Chemical group 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- CNOKQOBEMGIIAH-JYAZKYGWSA-N (2s)-2-[[(2s)-2-[[2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoic acid Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(O)=O CNOKQOBEMGIIAH-JYAZKYGWSA-N 0.000 claims 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 208000010201 Exanthema Diseases 0.000 claims 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims 1
- 206010021531 Impetigo Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 229940118430 Protease-activated receptor-2 antagonist Drugs 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 238000007792 addition Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims 1
- 230000004075 alteration Effects 0.000 claims 1
- 230000006229 amino acid addition Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000003185 calcium uptake Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical group C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims 1
- 229960003964 deoxycholic acid Drugs 0.000 claims 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 201000005884 exanthem Diseases 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 108091005995 glycated hemoglobin Proteins 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 125000001165 hydrophobic group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 125000000403 lignoceroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 claims 1
- 125000000628 margaroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 210000002752 melanocyte Anatomy 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 125000001402 nonanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000004848 polyfunctional curative Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 206010037844 rash Diseases 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 239000003229 sclerosing agent Substances 0.000 claims 1
- 108010014211 seryl-leucyl-isoleucyl-glycyl-arginyl-leucine Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022145694A JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2024207359A JP2025036429A (ja) | 2015-11-13 | 2024-11-28 | プロテアーゼ活性化受容体２のモジュレーター |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255334P | 2015-11-13 | 2015-11-13 | |
| US62/255,334 | 2015-11-13 | ||
| PCT/US2016/061489 WO2017083618A1 (en) | 2015-11-13 | 2016-11-11 | Protease-activated receptor-2 modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145694A Division JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537529A JP2018537529A (ja) | 2018-12-20 |
| JP2018537529A5 true JP2018537529A5 (enExample) | 2019-12-26 |
| JP7621728B2 JP7621728B2 (ja) | 2025-01-27 |
Family
ID=57394682
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018544771A Active JP7621728B2 (ja) | 2015-11-13 | 2016-11-11 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2022145694A Pending JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2024207359A Pending JP2025036429A (ja) | 2015-11-13 | 2024-11-28 | プロテアーゼ活性化受容体２のモジュレーター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022145694A Pending JP2022179508A (ja) | 2015-11-13 | 2022-09-13 | プロテアーゼ活性化受容体２のモジュレーター |
| JP2024207359A Pending JP2025036429A (ja) | 2015-11-13 | 2024-11-28 | プロテアーゼ活性化受容体２のモジュレーター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11091533B2 (enExample) |
| EP (1) | EP3374386B1 (enExample) |
| JP (3) | JP7621728B2 (enExample) |
| AU (1) | AU2016354478B2 (enExample) |
| ES (1) | ES2984663T3 (enExample) |
| WO (1) | WO2017083618A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160000791A1 (en) | 2014-07-07 | 2016-01-07 | Mayo Foundation For Medical Education And Research | Par1 modulation to alter myelination |
| EP3374386B1 (en) | 2015-11-13 | 2024-05-29 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
| US10550089B2 (en) * | 2016-05-12 | 2020-02-04 | Heptares Therapeutics Limited | Inhibitors of protease-activated receptor-2 |
| WO2020023417A1 (en) * | 2018-07-23 | 2020-01-30 | Enclear Therapies, Inc. | Methods of treating neurological disorders |
| KR20220011123A (ko) | 2019-04-11 | 2022-01-27 | 엔클리어 테라피스, 인크. | 뇌척수액 개선 방법 및 이를 위한 디바이스 및 시스템 |
| CN115190883A (zh) * | 2019-11-07 | 2022-10-14 | 伊利诺伊大学评议会 | 治疗脓毒症、动脉粥样硬化、血栓形成、中风、心脏病发作和炎症的肽和方法 |
| EP4090372A4 (en) * | 2020-01-14 | 2023-10-18 | Mayo Foundation for Medical Education and Research | Targeting par1 and par2 to regulate lipid and cholesterol abundance |
| AU2021355470A1 (en) | 2020-09-29 | 2023-06-01 | Enclear Therapies, Inc. | Subarachnoid fluid management method and system |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
| US5763575A (en) * | 1993-07-26 | 1998-06-09 | Cor Therapeutics, Inc. | Agonist and antagonist peptides of the C140 receptor |
| EP0835928A1 (en) | 1996-10-11 | 1998-04-15 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | Helicobacter pylori live vaccine |
| US7368531B2 (en) | 1997-03-07 | 2008-05-06 | Human Genome Sciences, Inc. | Human secreted proteins |
| US6747137B1 (en) | 1998-02-13 | 2004-06-08 | Genome Therapeutics Corporation | Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics |
| US6815200B1 (en) | 1998-02-17 | 2004-11-09 | The Uab Research Foundation | Modified adenovirus containing a fiber replacement protein |
| IL138798A0 (en) | 1998-04-07 | 2001-10-31 | Medimmune Inc | Vaccines and antibodies against bacterial pneumococcal infection |
| US6562958B1 (en) | 1998-06-09 | 2003-05-13 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics |
| WO2000034469A1 (en) | 1998-12-11 | 2000-06-15 | The Research Foundation Of State University Of New York At Albany | Compositions and methods for altering cell migration |
| US6703491B1 (en) | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| JP5356636B2 (ja) | 2000-04-21 | 2013-12-04 | タフツ メディカル センター インコーポレイテッド | Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法 |
| US7696168B2 (en) | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| US6773893B1 (en) | 2000-04-28 | 2004-08-10 | The Trustees Of Columbia University In The City Of New York | Human ABC1 promoter and assays based thereon |
| US7834146B2 (en) | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| US7214786B2 (en) | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| SE0201863D0 (en) | 2002-06-18 | 2002-06-18 | Cepep Ab | Cell penetrating peptides |
| CA2492938C (en) | 2002-08-02 | 2012-05-22 | Joseph H. Coggin, Jr. | Cancer vaccines containing epitopes of oncofetal antigen |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7189691B2 (en) | 2004-04-01 | 2007-03-13 | The Administrators Of The Tulane Educational Fund | Methods and compositions for treating leukemia |
| US20070207209A1 (en) | 2004-08-27 | 2007-09-06 | Murphy Christopher J | Trophic factor combinations for nervous system treatment |
| US7319142B1 (en) | 2004-08-31 | 2008-01-15 | Monsanto Technology Llc | Nucleotide and amino acid sequences from Xenorhabdus and uses thereof |
| EP1814911A2 (en) | 2004-11-04 | 2007-08-08 | New England Medical Center Hospitals, Inc. | G protein coupled receptor agonists and antagonists and methods of use |
| US8088976B2 (en) | 2005-02-24 | 2012-01-03 | Monsanto Technology Llc | Methods for genetic control of plant pest infestation and compositions thereof |
| WO2007061850A2 (en) | 2005-11-17 | 2007-05-31 | Massachusetts Institute Of Technology | Methods and systems for generating and evaluating peptides |
| AU2007218045B2 (en) | 2006-02-20 | 2011-11-10 | Phylogica Limited | Method of constructing and screening libraries of peptide structures |
| WO2008021290A2 (en) | 2006-08-09 | 2008-02-21 | Homestead Clinical Corporation | Organ-specific proteins and methods of their use |
| US9056905B2 (en) | 2007-05-21 | 2015-06-16 | Alderbio Holdings Llc | Antibodies to TNF-α and use thereof |
| JP4400668B2 (ja) | 2007-11-01 | 2010-01-20 | 株式会社豊田中央研究所 | 微小物体が固定化された固相体の製造方法及びその利用 |
| WO2009099580A2 (en) | 2008-02-05 | 2009-08-13 | Monsanto Technology, Llc | Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits |
| WO2010021822A2 (en) | 2008-07-30 | 2010-02-25 | The Regents Of The University Of California | Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites |
| CA2742509A1 (en) | 2008-11-04 | 2010-05-14 | Anchor Therapeutics, Inc. | Cxcr4 receptor compounds |
| BRPI0921815A2 (pt) | 2008-11-04 | 2018-10-09 | Anchor Therapeutics Inc | compostos receptores de apj |
| AU2010203698B2 (en) | 2009-01-06 | 2016-07-21 | C3 Jian, Inc. | Targeted antimicrobial moieties |
| US9012723B2 (en) | 2009-01-16 | 2015-04-21 | Monsanto Technology Llc | Isolated novel acid and protein molecules from soy and methods of using those molecules to generate transgene plants with enhanced agronomic traits |
| WO2010091294A2 (en) | 2009-02-05 | 2010-08-12 | The Regents Of The University Of California | New targeted antimicrobial moieties |
| JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| JP6225104B2 (ja) | 2011-04-08 | 2017-11-01 | タフツ メディカル センター インコーポレイテッドＴｕｆｔｓ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ，Ｉｎｃ． | ペプデューシンの設計および使用 |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9091651B2 (en) * | 2011-12-21 | 2015-07-28 | Integrated Diagnostics, Inc. | Selected reaction monitoring assays |
| EP3374386B1 (en) | 2015-11-13 | 2024-05-29 | Oasis Pharmaceuticals, LLC | Protease-activated receptor-2 modulators |
-
2016
- 2016-11-11 EP EP16801353.0A patent/EP3374386B1/en active Active
- 2016-11-11 AU AU2016354478A patent/AU2016354478B2/en active Active
- 2016-11-11 ES ES16801353T patent/ES2984663T3/es active Active
- 2016-11-11 JP JP2018544771A patent/JP7621728B2/ja active Active
- 2016-11-11 US US15/349,364 patent/US11091533B2/en active Active
- 2016-11-11 WO PCT/US2016/061489 patent/WO2017083618A1/en not_active Ceased
-
2020
- 2020-07-10 US US16/926,304 patent/US11732027B2/en active Active
-
2022
- 2022-09-13 JP JP2022145694A patent/JP2022179508A/ja active Pending
-
2024
- 2024-11-28 JP JP2024207359A patent/JP2025036429A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537529A5 (enExample) | ||
| ES2984663T3 (es) | Moduladores del receptor 2 activados por proteasa | |
| US9683019B2 (en) | Cyclic polypeptides for the treatment of heart failure | |
| CN114341161A (zh) | 白细胞介素-23受体的肽抑制剂及其用于治疗炎症性疾病的用途 | |
| JP2017530090A5 (enExample) | ||
| JP2010508305A5 (enExample) | ||
| US20230287051A1 (en) | Inhibitors of complement factor c3 and their medical uses | |
| US10213476B2 (en) | Compstatin analogs with improved potency and pharmacokinetic properties | |
| EP4251130A1 (en) | Compositions and methods for selective depletion of target molecules | |
| JP2014511866A5 (enExample) | ||
| US8003610B2 (en) | Bradykinin B2 receptor antagonist peptide from amphibian skin | |
| WO2015143581A1 (zh) | 靶特异性双突变体融合蛋白质及其制备工艺 | |
| JP2018519254A5 (enExample) | ||
| WO2016022610A1 (en) | Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same | |
| JP5698977B2 (ja) | メタスチン誘導体およびその用途 | |
| JP2023514420A (ja) | 変異型ｒａｓタンパク質を標的化する分子 | |
| CN116199744B (zh) | 一种结合fgfr2受体的多肽及其用途 | |
| Badgery-Parker et al. | Receptor binding profile of neuropeptide γ and its fragments: Comparison with the nonmammalian peptides carassin and ranakinin at three mammalian tachykinin receptors | |
| JP2002534996A5 (enExample) | ||
| TW202304957A (zh) | Kv1.3阻斷劑 | |
| TW202042836A (zh) | 血球凝集素結合肽 | |
| JPWO2023282281A5 (enExample) | ||
| EP4611787A1 (en) | Ccr2 inhibitors and methods of use | |
| CN117136192A (zh) | 缀合的铁调素模拟物 | |
| AU2020299636A1 (en) | Compositions and methods of use |